Olympus Plasma Hysteroscopic Resection and Vaporization Unveiled at the 2017 American Congress of Obstetricians and Gynecologists Annual Meeting

LG Thin-Clients Feature Built-in RFID Capabilities Optimized for Use in Healthcare Facilities

Supporting its mission to help healthcare providers streamline operations and deliver exceptional patient care, LG Business Solutions USA introduced a new LG thin client...

Experien Group Acquired by Veranex

Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets.

Olympus has received FDA 510(k) clearance of claims that the bipolar electrosurgery featured with its plasma hysteroscopic resection and vaporization system has lower risks of electrolyte imbalance (hyponatremia) compared to monopolar electrosurgery. This advantage can lead to improved patient outcomes. (PRNewsfoto/Olympus America Inc.)

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today that it has released the new plasma hysteroscopic resection and vaporization full portfolio of products. These products have received FDA 510(k) clearance of claims that the bipolar electrosurgery featured with its plasma hysteroscopic resection and vaporization system has lower risks of electrolyte imbalance (hyponatremia) compared to monopolar electrosurgery. In addition to improved patient outcomes, the system benefits include precision in cutting, better visibility, and cost-savings potential through the portfolio of plasma-enabled electrodes for a wide range of hysteroscopic procedures.

Plasma resection and vaporization, used in other medical specialties, creates an electrically conductive gas cloud of vapor and charged particles. During gynecologic procedures, plasma is created by the combination of radio frequency, energy and saline. Due to its conductivity, the plasma allows the energy to cross into the targeted tissue at lower energy levels than with more traditional approaches. This effect leads to lower operating temperatures and therefore less thermal spread.

The Olympus 8.5 mm hystero-resectoscope, for use with the world’s first 4 MM high definition telescope, is designed with extra-low dispersion glass and offers several dedicated plasma electrodes, offering a variety of treatment options in gynecology:

  • Vaporization electrodes, which eliminate the need for chip removal (removing the need for multiple resectoscope reinsertions and designed for procedural efficiency).
  • Variety of loop sizes for resection and coagulation of polyps, myomas and the endometrium, which allows for fewer cuts, thereby enabling quicker resection and operating time.
  • Needle electrode for septum removal.

“The Olympus plasma hysteroscopic resection and vaporization system advances operative hysteroscopy to a new level of capability,” said Dr. Benjamin Gocial at Main Line Fertility.

“Olympus builds upon its excellent track record with plasma resection and vaporization through this 510(k) clearance, and we expect enthusiastic adoption of the technology in gynecology,” said Randy Clark, Group Vice President of the Surgical Division at Olympus America Inc. “We have aimed not only to bring improved patient outcomes to our customers, but to provide an advanced gynecology portfolio that is cost effective for Hospitals and Ambulatory Surgery Centers.”

The plasma hysteroscopic system will be showcased at the American Congress of Obstetricians and Gynecological Annual Meeting (ACOG) May 6-9 in San Diego, CA at booth #948. To learn more about the plasma hysteroscopic resection and vaporization system from Olympus, please call 1-800-848-9024 or visit us at http://medical.olympusamerica.com/procedure/hysteroscopy

spot_img

DON'T MISS

Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.